Skip Navigation
Search site

We are building you a better website. You might be interested to see the new look here, and let us know what you think.

Report publishes new information across specialised pulmonary hypertension centres

31 March, 2015: Diagnosis information by specialised pulmonary hypertension centre has been published for the first time today by the Health and Social Care Information Centre.

The data is published as part of the National Audit of Pulmonary Hypertension (NAPH), which is a nationwide audit of all specialised pulmonary hypertension centres in the United Kingdom. The purpose of the audit is to describe clinical practice, provide epidemiological information for future service planning and measure clinical outcomes.

Specialised centres are responsible for making an accurate diagnosis, initiating disease targeted drug therapy6 and, where appropriate, undertaking the long term management of patients with diverse causes of pulmonary hypertension. Figures for all patients across specialised centres in 2013-14 are covered within the report.

The report also publishes for the first time:

  • Therapy analysis by specialised centre.
  • A comparison of operated and not operated chronic thromboembolic pulmonary hypertension.
  • An analysis of distance from a specialised centre as an influence on referral patterns.
  • New analyses concerning time to failure of drug therapies.

ENDS


Notes to editors

  1. The Health and Social Care Information Centre (HSCIC) was established on April 1 2013 as an Executive Non Departmental Public Body (ENDPB). It is England's trusted data source, delivering high quality information and IT systems to drive better patient services, care and outcomes. Its work includes publishing more than 220 statistical publications annually; providing a range of specialist data services; managing informatics projects and programmes and developing and assuring national systems against appropriate contractual, clinical safety and information standards.
  2. Pulmonary hypertension is defined by a mean pulmonary arterial pressure (mPAP) ≥25 mmHg at rest usually confirmed by right heart catheterization.
  3. The National Pulmonary Hypertension Audit has been prepared in partnership with the Health and Social Care Information Centre, National Pulmonary Hypertension Association (PHA UK), National Pulmonary Hypertension Centres of the UK and Ireland Physicians Committee, NHS England, National Services Division (NSD) and Welsh Health Specialised Services Committee. More information can be found here: http://www.hscic.gov.uk/ph
  4. All reporting of data in the audit is the responsibility of the specialised pulmonary hypertension centre irrespective of where the activity occurred.
  5. Diagnoses are reported according to the 2008 Dana Point clinical classification. The recent changes made to the Nice 2013 clinical classification were minor and given the amount of work to reclassify patients in the database the Pulmonary Hypertension Outcomes Group decided to maintain the Dana Point classification.
  6. The treatment of pulmonary hypertension with the disease targeted drug therapies is controlled by the NHS England drug policies on pulmonary hypertension drugs which were last updated in May 2014. Scotland, Wales and Northern Ireland largely follow these policies. These policies do not apply to children. These drug policies must be borne in mind when interpreting the data collected about drug prescriptions.
  7. For media enquires or interview requests please contact media@hscic.gov.uk or telephone 0300 30 33 888. Please note the change to our media line number.
Close iCM Form